Drug Profile
Research programme: anticancer monoclonal antibodies - Champions Oncology/Eisai Inc
Latest Information Update: 23 Jan 2020
Price :
$50
*
At a glance
- Originator Morphotek
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 04 Apr 2011 Champions Biotechnology is now called Champions Oncology
- 03 Nov 2010 Champions Biotechnology receives Qualifying Therapeutics Discovery Project grant from the US Department of Health and Human Services for oncology candidate drug development in Cancer